IGHV Mutation Analysis by Sequencing
0040227
Ordering Recommendation
Determine risk group in newly diagnosed CLL.
Mnemonic
IGHV MUT
Methodology
Polymerase Chain Reaction/Sequencing
Performed
Varies
Reported
12-14 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Lavender (EDTA) or bone marrow (EDTA).  
Specimen Preparation
Transport 5 mL whole blood OR 3 mL bone marrow. (Min: 1 mL whole blood OR 1 mL bone marrow) Specimens must be received within 48 hours of collection due to lability of RNA..  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Serum or plasma. Frozen or clotted specimens. Specimens collected in anticoagulants other than EDTA. Severely hemolyzed specimens.  
Remarks
  
Stability
Ambient: 1 hour; Refrigerated: 48 hours; Frozen: Unacceptable  
Reference Interval
   
Interpretive Data
Refer to report.

See Compliance Statement B: www.aruplab.com/CS
Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
 
Note
This assay is designed for individuals with a confirmed diagnosis of CLL, and for these individuals testing will include sequencing.  All other diagnoses will terminate after amplification and will not have the sequencing component.
CPT Code(s)
81263
Components
Component Test Code*Component Chart Name
0040229IGHV Mutation Analysis by Sequencing
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • IGHV genes
  • IGHV mutation status